Company News_Frontera Therapeutics, Inc.

: Frontera’s Study Report on ” Case Studies of Resolving rAAV Aggregation & Removing Empty Vectors ” will be presented in Gene Therapy for Rare Disorders 2024

Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been invited to deliver a presentation focusing on the vital topic of “Case Studies: Overcoming Challenges in rAAV Drug Manufacturing.” on March 27, 2024. This presentation falls within the Manufacturing category and will delve into two pivotal case studies aimed at resolving common manufacturing hurdles encountered in purifying rAAV drugs.
2024-03-18

: Frontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies

BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants.
2024-01-23

: Preliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress

Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023).
2023-12-10

: Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment

Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu Weihong, and Professor Dai Rongping.
2023-12-05

: Frontera Therapeutics announces CDE clearance to initiate clinical trial of a First-in-class gene therapy for the treatment of RPGR-associated X-linked Retinitis Pigmentosa

BEDFORD, Mass., and SHANGHAI, China, Nov 6th, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd (referred to as Frontera) announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has given clearance of the Investigational New Drug (IND) application to begin a clinical trial of an innovative gene therapy drug, FT-002, for the treatment of RPGR (Retinitis Pigmentosa GTPase Regulator) – associated X-linked Retinitis Pigmentosa (XLRP).
2023-11-06

: The Frontera’s third gene therapy treatment has been approved by CDE for clinical studies

BEDFORD, Mass., and SHANGHAI, China, July 12, 2023 – An application for an investigational study in human patients with FT-004, an innovative gene therapy drug independently developed by Frontera Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as “Frontera Biotechnology”), was approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration for the indication of hemophilia B (endogenous FIX activity ≤ 2%). This is the third innovative AAV gene therapy product approved for investigational clinical studies by Frontera Biotech.
2023-07-14

Company News